Free tool
FAERS Monitor: Glyxambi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206073 or its brand name (Glyxambi, Empagliflozin, Linagliptin). Reports on generic versions are filed under their own applications.
Reports
1,966
Serious
894
45% of reports
Hospitalization
479
Death reported
65
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased152
- diabetic ketoacidosis149
- nausea106
- fungal infection92
- weight decreased87
- dizziness76
- vomiting71
- urinary tract infection66
- fatigue59
- drug ineffective56
- diarrhoea50
- headache49
- dehydration48
- off label use43
- euglycaemic diabetic ketoacidosis41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 209 |
| 2016 | 298 |
| 2017 | 172 |
| 2018 | 182 |
| 2019 | 211 |
| 2020 | 192 |
| 2021 | 165 |
| 2022 | 122 |
| 2023 | 142 |
| 2024 | 105 |
| 2025 | 96 |
| 2026 | 72 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,193 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| euglycaemic diabetic ketoacidosisSignal | 41 | 107.3 | 79.1 | 4,171 |
| diabetic ketoacidosisSignal | 149 | 66.8 | 57.2 | 9,539 |
| fungal infectionSignal | 92 | 29.6 | 24.2 | 2,512 |
| blood glucose increasedSignal | 152 | 8.6 | 7.4 | 1,027 |
| urinary tract infectionSignal | 66 | 4.1 | 3.3 | 155 |
| dehydrationSignal | 48 | 3.9 | 2.9 | 99 |
| weight decreasedSignal | 87 | 3.3 | 2.7 | 142 |
| dizziness | 76 | 1.6 | 1.3 | 18 |
| vomiting | 71 | 1.6 | 1.3 | 16 |
| nausea | 106 | 1.4 | 1.2 | 14 |
| headache | 49 | 0.8 | 0.6 | 1 |
| diarrhoea | 50 | 0.8 | 0.6 | 2 |
| fatigue | 59 | 0.8 | 0.6 | 3 |
| off label use | 43 | 0.5 | 0.4 | 19 |
| drug ineffective | 56 | 0.5 | 0.4 | 39 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.